Recent Developments

March 1, 2007 – EXT completes design and synthesis of Catalase-SKL® compounds which will now be used in collaborative in vitro, ex vivo, and clinical studies.

February 1, 2007 – Design and cloning process completed in preparation for dermal applications testing.

August 1, 2006 – EXT opens laboratories at TechTown, to bolster its in-house research capabilities.

June 7, 2005 – EXT announces the start of preliminary animal testing of Catalase-SKL compounds. Experiments will be conducted at the Van Andel Research Institute in Grand Rapids, MI, under contract to EXT. Various Catalase-SKL compounds will be evaluated for their delivery capability, bio-distribution and, most importantly, impact on aging and other critical physiological functions.

October 14, 2004 -- EXT secures exclusive worldwide rights to Catalase-SKL technologies and patents from Wayne State University and the University of Western Ontario. The company will now continue the research and development process, which includes the production of Catalase-SKL compounds, to be used in subsequent animal tests. “This is a crucial step towards marketing these important discoveries,” said company President Dr. Stanley R. Terlecky.